Valneva's share price has fluctuated sharply in recent weeks on news about the company's COVID-19 vaccine candidate.
(Reporting by Tassilo Hummel, editing by GV De Clercq)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.434 EUR | +1.60% | -0.29% | -27.25% |
Apr. 11 | Valneva: Deep Track Biotechnology Master holds less than 5% of the capital | CF |
Mar. 26 | Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate | MT |
PARIS (Reuters) - Shares in biotech firm Valneva dropped as much as 6.9% on Tuesday after the European Union drug regulator said the firm's COVID-19 vaccine was under an EU rolling review but it was still awaiting some additional data.
Valneva's share price has fluctuated sharply in recent weeks on news about the company's COVID-19 vaccine candidate.
(Reporting by Tassilo Hummel, editing by GV De Clercq)
1st Jan change | Capi. | |
---|---|---|
-27.25% | 502M | |
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |